Why the study?
The study evaluated the prognostic value and incremental predictive utility of NAFLD for MACE in patients with suspected CAD evaluated by CCTA and CT-FFR.
Does the presence of non-alcoholic fatty liver disease predict major adverse cardiovascular events in patients with suspected coronary artery disease evaluated by CCTA?
Does the presence of non-alcoholic fatty liver disease predict major adverse cardiovascular events in patients with suspected coronary artery disease evaluated by CCTA?
The presence of NAFLD is an independent prognostic indicator for MACE in suspected CAD patients, and incorporating NAFLD into risk stratification models with CCTA and CT-FFR significantly improves predictive accuracy.
Answers are grounded in this paper and cite their sources.
May enhance MACE risk stratification in suspected CAD; hypothesis-generating, requiring prospective validation before practice change.
OBJECTIVE: This study assessed the prognostic value of non-alcoholic fatty liver disease (NAFLD) in predicting major adverse cardiovascular events (MACE) in patients with suspected coronary artery disease (CAD), using coronary computed tomography angiography (CCTA) and CT-derived fractional flow reserve (CT-FFR). METHODS: In this retrospective study, patients who underwent both CCTA and non-contrast liver/spleen CT at Dalian Medical University First Affiliated Hospital from January 2017 to December 2018 were included. NAFLD was diagnosed via CT and clinical history. MACE included cardiovascular/cerebrovascular death, all-cause mortality, myocardial infarction, unstable angina hospitalization, unplanned revascularization, and stroke. Patients were divided into NAFLD and non-NAFLD groups. Cox regression assessed the association between NAFLD and MACE, adjusting for cardiovascular risk factors, CCTA findings, and CT-FFR results. Subgroup and time-dependent C-index analyses evaluated prognostic performance across populations and follow-up duration. RESULTS: Among 2,981 patients (737 with NAFLD), 408 experienced MACE over a median 68-month of follow-up. The NAFLD group had higher CAD-RADS scores, high-risk plaque, coronary calcification, and CT-FFR positivity, all p < 0.05. NAFLD independently predicted MACE (adjusted HR: 1.39; 95% CI: 1.15, 1.73; p < 0.001), especially in males, smokers, hypertensive and non-diabetic patients, and those with non-obstructive CAD or normal CT-FFR. Including NAFLD improved model performance at all time points, with C-index at 60 months of 0.753 vs. 0.727 (model2) and 0.695 (model 1), p < 0.001. CONCLUSION: NAFLD serves as an independent prognostic indicator for MACEs in patients with suspected CAD. The incorporation of NAFLD into risk stratification models significantly enhances predictive accuracy, especially within high-risk sub-populations.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: